|
11 Companies |
|
5 Products |
|
5 Products |
|
5 Mechanisms of Action |
|
0 Trials |
|
118 News |
|
| «123» |
- |||||| Enrollment open, Trial initiation date, Trial primary completion date: Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. (clinicaltrials.gov) - Apr 14, 2015
P3, N=1560, Recruiting, Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Feb 2015 | Trial primary completion date: Apr 2015 --> Nov 2015
- | Zostavax (zoster vaccine live) / Merck (MSD)
New P4 trial: Varicella Zoster Vaccine in Patients With Plaque Psoriasis Treated With Biologic Therapy (clinicaltrials.gov) - Apr 3, 2015
P4, N=50, Not yet recruiting, Sponsor: Innovaderm Research Inc.
- |||| Varivax (varicella virus vaccine live) / Merck (MSD)
Trial primary completion date: Evaluation of Immunogenicity and Safety of VARIVAX (clinicaltrials.gov) - Mar 12, 2015
P3, N=600, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Feb 2015 | Trial primary completion date: Apr 2015 --> Nov 2015 Trial primary completion date: Feb 2015 --> Jun 2015
- | Barycela (varicella II vaccine) / GC Biopharma
New P1 trial: Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults (clinicaltrials.gov) - Feb 20, 2015
P1, N=39, Not yet recruiting, Sponsor: Green Cross Corporation
- Biomarker, Phase classification: Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccines (clinicaltrials.gov) - Feb 19, 2015
P=N/A, N=48, Completed, Sponsor: University of Surrey
Trial primary completion date: Feb 2015 --> Jun 2015 Phase classification: P1 --> P=N/A
- ||||| Zostavax (zoster vaccine live) / Merck (MSD)
Trial initiation date: ZOSTAVAX(R) Local Registration Trial (V211-019) (clinicaltrials.gov) - Feb 5, 2015
P3, N=150, Completed, Sponsor: Merck Sharp & Dohme Corp.
Phase classification: P1 --> P=N/A Initiation date: Mar 2006 --> Mar 2007
- Varivax (varicella virus vaccine live) / Merck (MSD)
Enrollment change, Trial withdrawal: A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX (clinicaltrials.gov) - Jan 28, 2015
P3, N=0, Withdrawn, Sponsor: Merck Sharp & Dohme Corp.
Initiation date: Mar 2006 --> Mar 2007 N=520 --> 0 | Not yet recruiting --> Withdrawn
- ||||| Varivax (varicella virus vaccine live) / Merck (MSD)
Enrollment closed, Trial primary completion date: Evaluation of Immunogenicity and Safety of VARIVAX (clinicaltrials.gov) - Jan 20, 2015
P3, N=600, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=520 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Feb 2015
- | Vaqta (hepatitis A vaccine, inactivated) / Merck (MSD), ProQuad (measles, mumps, rubella and varicella virus vaccine live) / Merck (MSD)
Phase classification: Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) (clinicaltrials.gov) - Dec 5, 2014
P4, N=653, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Feb 2015 Phase classification: P3 --> P4
- || Zostavax (zoster vaccine live) / Merck (MSD)
Enrollment closed, Trial primary completion date, IO biomarker: Zoster Vaccine Response in the Frail Elderly (clinicaltrials.gov) - Nov 3, 2014
P=N/A, N=250, Active, not recruiting, Sponsor: McMaster University
Phase classification: P3 --> P4 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Dec 2014
- Trial completion: Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine (clinicaltrials.gov) - Sep 4, 2014
P4, N=716, Completed, Sponsor: Changchun Keygen Biological Products Co., Ltd.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2013 --> Dec 2014 Recruiting --> Completed
- inactivated VZV vaccine (V212) / Merck (MSD)
Enrollment change, Trial withdrawal: A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Healthy Adults (V212-014) (clinicaltrials.gov) - Sep 4, 2014
P3, N=0, Withdrawn, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed N=315 --> 0 | Not yet recruiting --> Withdrawn
- Enrollment open: Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine (clinicaltrials.gov) - Jul 3, 2014
P4, N=600, Recruiting, Sponsor: Changchun Keygen Biological Products Co., Ltd.
N=315 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- |||||||||| inactivated VZV vaccine (V212) / Merck (MSD)
New P3 trial: A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Healthy Adults (V212-014) (clinicaltrials.gov) - Jul 2, 2014
P3, N=315, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | New P4 trial: Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine (clinicaltrials.gov) - Jun 27, 2014
P4, N=600, Not yet recruiting, Sponsor: Changchun Keygen Biological Products Co., Ltd.
- Biomarker, Trial primary completion date: Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccines (clinicaltrials.gov) - May 6, 2014
P1, N=48, Completed, Sponsor: University of Surrey
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2013 --> Jan 2014
- Biomarker, Enrollment change: Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccines (clinicaltrials.gov) - May 6, 2014
P1, N=48, Completed, Sponsor: University of Surrey
Trial primary completion date: Dec 2013 --> Jan 2014 N=24 --> 48
- | Biomarker, Trial completion: Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccines (clinicaltrials.gov) - May 6, 2014
P1, N=48, Completed, Sponsor: University of Surrey
N=24 --> 48 Recruiting --> Completed
- |||| Trial primary completion date: Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children (clinicaltrials.gov) - Apr 23, 2014
P3, N=716, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Trial primary completion date: May 2014 --> Mar 2014
- ||| Trial completion date: Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children (clinicaltrials.gov) - Apr 23, 2014
P3, N=716, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: May 2014 --> Mar 2014 Trial completion date: May 2014 --> Mar 2014
- ||||||| Trial completion: Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children (clinicaltrials.gov) - Apr 23, 2014
P3, N=716, Completed, Sponsor: GlaxoSmithKline
Trial completion date: May 2014 --> Mar 2014 Active, not recruiting --> Completed
- Zostavax (zoster vaccine live) / Merck (MSD)
Enrollment closed: ZOSTAVAX (clinicaltrials.gov) - Apr 9, 2014
P1, N=34, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||| Varivax (varicella virus vaccine live) / Merck (MSD)
Enrollment open: Evaluation of Immunogenicity and Safety of VARIVAX (clinicaltrials.gov) - Mar 18, 2014
P3, N=600, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Trial completion: Shingles: Immune Effects of Tai Chi (clinicaltrials.gov) - Feb 22, 2014
P2, N=140, Completed, Sponsor: National Institute on Aging (NIA)
Not yet recruiting --> Recruiting No longer recruiting --> Completed
- ||||| Zostavax (zoster vaccine live) / Merck (MSD)
Enrollment closed: Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029) (clinicaltrials.gov) - Feb 12, 2014
P3, N=600, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
No longer recruiting --> Completed Completed --> Active, not recruiting
- |||||||||| Varivax (varicella virus vaccine live) / Merck (MSD)
New P3 trial: Evaluation of Immunogenicity and Safety of VARIVAX (clinicaltrials.gov) - Feb 11, 2014
P3, N=600, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- ||||||| ProQuad (measles, mumps, rubella and varicella virus vaccine live) / Merck (MSD)
Trial completion: Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) (clinicaltrials.gov) - Feb 10, 2014
P3, N=1413, Completed, Sponsor: Merck Sharp & Dohme Corp.
Completed --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion: Cytokine Production and Immunity to Varicella Zoster Virus (VZV) in Elderly Recipients of Zoster Vaccine (clinicaltrials.gov) - Jan 26, 2014
P=N/A, N=26, Completed, Sponsor: Columbia University
Active, not recruiting --> Completed Recruiting --> Completed
- ||||| Enrollment closed: Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children (clinicaltrials.gov) - Jan 15, 2014
P3, N=720, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| New P3 trial: Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. (clinicaltrials.gov) - Nov 7, 2013
P3, N=1560, Not yet recruiting, Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
- Enrollment change: Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine (clinicaltrials.gov) - Oct 13, 2013
P4, N=368, Completed, Sponsor: Changchun Keygen Biological Products Co., Ltd.
Recruiting --> Active, not recruiting N=300 --> 368
- Enrollment change: Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine (clinicaltrials.gov) - Oct 13, 2013
P4, N=497, Completed, Sponsor: Changchun Keygen Biological Products Co., Ltd.
N=300 --> 368 N=368 --> 497
- Trial completion: Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine (clinicaltrials.gov) - Oct 13, 2013
P4, N=368, Completed, Sponsor: Changchun Keygen Biological Products Co., Ltd.
N=368 --> 497 Recruiting --> Completed
- Biomarker, Trial initiation date: Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccines (clinicaltrials.gov) - Sep 16, 2013
P1, N=24, Recruiting, Sponsor: University of Surrey
Recruiting --> Completed Initiation date: Jan 2013 --> Sep 2013
- Biomarker, Enrollment open: Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccines (clinicaltrials.gov) - Sep 16, 2013
P1, N=24, Recruiting, Sponsor: University of Surrey
Initiation date: Jan 2013 --> Sep 2013 Not yet recruiting --> Recruiting
- Zostavax (zoster vaccine live) / Merck (MSD)
Trial completion: Zostavax in Systemic Lupus Erythematosus (clinicaltrials.gov) - Sep 15, 2013
P1, N=20, Completed, Sponsor: Oklahoma Medical Research Foundation
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial completion: Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine (clinicaltrials.gov) - Sep 5, 2013
P4, N=497, Completed, Sponsor: Changchun Keygen Biological Products Co., Ltd.
Recruiting --> Completed Recruiting --> Completed
- | Zostavax (zoster vaccine live) / Merck (MSD)
New P4 trial: T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020 (clinicaltrials.gov) - Jul 28, 2013
P4, N=150, Active, not recruiting, Sponsor: Stanford University
- Trial withdrawal: Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines (clinicaltrials.gov) - Jul 17, 2013
P=N/A, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines (clinicaltrials.gov) - Jul 17, 2013
P=N/A, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Not yet recruiting --> Withdrawn N=3000 --> 0
- | Trial initiation date: SPS: Shingles Prevention Study (clinicaltrials.gov) - Jul 1, 2013
P3, N=38456, Completed, Sponsor: Department of Veterans Affairs
N=3000 --> 0 Initiation date: Dec 1997 --> Nov 1998
- Trial completion, HEOR: VARICOMP: Varicella-related Hospitalizations in Turkey (clinicaltrials.gov) - Jun 25, 2013
P=N/A, N=1800, Completed, Sponsor: Eskisehir Osmangazi University
Initiation date: Dec 1997 --> Nov 1998 Not yet recruiting --> Completed
- Enrollment change: Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients (clinicaltrials.gov) - Jun 20, 2013
P=N/A, N=4807, Completed, Sponsor: University of Colorado, Denver
Not yet recruiting --> Completed N=13784 --> 4807
- Trial completion: Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients (clinicaltrials.gov) - Jun 20, 2013
P=N/A, N=4807, Completed, Sponsor: University of Colorado, Denver
N=13784 --> 4807 Enrolling by invitation --> Completed
- |||| inactivated VZV vaccine (V212) / Merck (MSD)
Trial completion: A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009) (clinicaltrials.gov) - Mar 25, 2013
P2, N=354, Completed, Sponsor: Merck Sharp & Dohme Corp.
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- | New P4 trial: Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine (clinicaltrials.gov) - Mar 21, 2013
P4, N=368, Completed, Sponsor: Changchun Keygen Biological Products Co., Ltd.
- | New P4 trial: Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine (clinicaltrials.gov) - Mar 18, 2013
P4, N=497, Completed, Sponsor: Changchun Keygen Biological Products Co., Ltd.
- Trial completion: Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX) in North Carolina (clinicaltrials.gov) - Mar 3, 2013
P=N/A, N=91, Completed, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Varivax (varicella virus vaccine live) / Merck (MSD)
Trial initiation date: A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX (clinicaltrials.gov) - Feb 28, 2013
P3, N=520, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Initiation date: Jun 2013 --> Jul 2014
- Zostavax (zoster vaccine live) / Merck (MSD)
Trial withdrawal: Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study (clinicaltrials.gov) - Feb 27, 2013
P1/2, N=0, Withdrawn, Sponsor: University of Zurich
Initiation date: Jun 2013 --> Jul 2014 Not yet recruiting --> Withdrawn